Don’t Let Recent momentum Confuse Your Outlook on Obalon Therapeutics Inc. [OBLN]

Obalon Therapeutics Inc. [OBLN] stock is up 18.93 while the S&P 500 has risen 0.01% on Tuesday, 12/01/20. While at the time of this article, OBLN ATR is sitting at 0.08, with the beta value at -0.93. This stock’s volatility for the past week remained at 6.57%, while it was 10.73% for the past 30-day period. OBLN has risen $0.18 from the previous closing price of $0.95 on volume of 12.67 million shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 6, November 2020, Obalon Announces Third Quarter 2020 Financial Results. According to news published on Yahoo Finance, Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020.

Analyst Birdseye View:

The most recent analyst activity for Obalon Therapeutics Inc. [NASDAQ:OBLN] stock was on August 03, 2018, when it was Reiterated with a Hold rating from Stifel, which also lowered its 12-month price target on the stock from $3 to $2. Before that, on February 25, 2019, Stifel Recapitulated a Buy rating and elevated its amount target to $3.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.62 and a peak of $2.14. Right now, the middling Wall Street analyst 12-month amount mark is $0.75. At the most recent market close, shares of Obalon Therapeutics Inc. [NASDAQ:OBLN] were valued at $1.13.


Obalon Therapeutics Inc. [NASDAQ:OBLN] most recently reported quarterly sales of 44.0 million, which represented growth of -86.80%. This publicly-traded organization’s revenue is $96,500 per employee, while its income is -$696,353 per employee. This company’s Gross Margin is currently 29.50%, its Pretax Margin is -721.61, and its Net Margin is -721.61. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -93.25, -163.53, -110.62 and -160.39 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 6.64 and the whole liability to whole assets at 5.53. It shows enduring liability to the whole principal at 3.34 and enduring liability to assets at 0.03 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.9200 points at 1st support level, the second support level is making up to 0.8900. But as of 1st resistance point, this stock is sitting at 0.9800 and at 1.0100 for 2nd resistance point.

Obalon Therapeutics Inc. [OBLN] reported its earnings at -$0.2 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.07/share signifying the difference of -0.13 and -185.70% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.54 calling estimates for -$0.3/share with the difference of -0.24 depicting the surprise of -80.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Obalon Therapeutics Inc. [NASDAQ:OBLN] is 1.80. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.53. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2.73 and it’s amount to book ratio is 0.93.